Hacohen, Y;
Banwell, B;
Ciccarelli, O;
(2020)
What does first-line therapy mean for paediatric multiple sclerosis in the current era?
Multiple Sclerosis Journal
10.1177/1352458520937644.
(In press).
Preview |
Text
Ciccarelli_What does first-line therapy mean for paediatric multiple sclerosis in the current era_AAM.pdf - Accepted Version Download (231kB) | Preview |
Abstract
Paediatric multiple sclerosis (MS) is associated with higher relapse rate, rapid magnetic resonance imaging lesion accrual early in the disease course and worse cognitive outcome and physical disability in the long term compared to adult-onset disease. Current treatment strategies are largely centre-specific and reliant on adult protocols. The aim of this review is to examine which treatment options should be considered first line for paediatric MS and we attempt to answer the question if injectable first-line disease-modifying therapies (DMTs) are still an optimal option. To answer this question, we review the effects of early onset disease on clinical course and outcomes, with specific considerations on risks and benefits of treatments for paediatric MS. Considering the impact of disease activity on brain atrophy, cognitive impairment and development of secondary progressive MS at a younger age, we would recommend treating paediatric MS as a highly active disease, favouring the early use of highly effective DMTs rather than injectable DMTs.
| Type: | Article |
|---|---|
| Title: | What does first-line therapy mean for paediatric multiple sclerosis in the current era? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/1352458520937644 |
| Publisher version: | https://doi.org/10.1177%2F1352458520937644 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | Disease-modifying therapies, paediatric multiple sclerosis, second-line treatment, treatment response, outcome measurement, magnetic resonance imaging |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10108128 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
